Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 9/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542578 | 0.94 | PIM1 (0.34) | PIM1HTR2CATMKMT2AGFER | |
| SCHEMBL3543039 | 0.84 | HTR2C (0.34) | PIM1HTR2CKMT2AGFERGHSR | |
| SCHEMBL3542155 | 0.82 | PIM1 (0.42) | PIM1HTR2C | |
| SCHEMBL3544618 | 0.82 | CCNT1 (0.40) | PDE2A | |
| SCHEMBL3537875 | 0.82 | ALDH1A1 (0.37) | HTR2CKMT2AGFERTRPC3TRPC6 | |
| SCHEMBL3540873 | 0.81 | ALDH1A1 (0.47) | HTR2CKMT2APDE2AMEN1 | |
| SCHEMBL3537882 | 0.81 | PIM1 (0.39) | PIM1HTR2CKMT2AGHSRPDE2A | |
| SCHEMBL3545577 | 0.80 | ALDH1A1 (0.43) | KMT2AGFERTRPC3TRPC6MEN1 | |
| SCHEMBL3538082 | 0.80 | SHMT2 (0.43) | HTR2CTRPC3TRPC6 | |
| SCHEMBL3540062 | 0.80 | PIM1 (0.40) | PIM1PDE2APIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | PIM1 1286/4885HTR2C 422/4885ATM 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.